Gilead's lenacapavir injection, shown in a rollout of its approved HIV treatment form called Sunlenca, is up for a PrEP approval decision on June 19 (Credit: Gilead)
With HIV prevention under attack, how might Gilead’s new PrEP injection fare?
A groundbreaking new therapy that can almost entirely prevent HIV is days away from an FDA decision — but a mix of recent federal politics and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
